Thus, the study confirmed the antitumor effect of metformin in ovarian cancer cells in vivo, and showed that metformin decreased tumor volume and weight in a dose-dependent manner as well as effectively induced ASK1 phosphorylation. The gene discussed is MAP3K5; the disease is ovarian cancer.